Research Papers:

Overexpression of miR-26b decreases the cisplatin-resistance in laryngeal cancer by targeting ATF2

Linli Tian, Jiarui Zhang, Xiuxia Ren, Xinyu Liu, Wei Gao, Chen Zhang, Yanan Sun and Ming Liu _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:79023-79033. https://doi.org/10.18632/oncotarget.20784

Metrics: PDF 1463 views  |   HTML 2044 views  |   ?  


Linli Tian1, Jiarui Zhang1, Xiuxia Ren1, Xinyu Liu1, Wei Gao1, Chen Zhang1, Yanan Sun1 and Ming Liu1

1Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, China, 150086

Correspondence to:

Ming Liu, email: [email protected]

Keywords: laryngeal cancer, Hep-2/R, miR-26b, ATF2, cisplatin

Received: July 10, 2017    Accepted: August 09, 2017    Published: September 08, 2017


Cisplatin is a common used chemotherapeutic drug for the treatment of laryngeal cancer. However, drug-resistance is a major obstacle in platinum-based chemotherapy for laryngeal cancer. Recent studies have demonstrated that dysregulation of microRNAs (miRNAs) is responsible for chemoresistance in multiple cancers including laryngeal cancer, but the potential mechanisms are required to be explored. In the present study, we constantly exposed the laryngeal cancer cell line Hep-2 with cisplatin to establish a cisplatin-resistant laryngeal cancer cell model (Hep-2/R). We found that Hep-2/R cells exhibited obvious resistance to cisplatin compared to the Hep-2 cells. However, overexpression of miR-26b significantly decreased the half maximal inhibitory concentration (IC50) of cisplatin to Hep-2/R. Mechanically, miR-26b in Hep-2/R decreased the expression of ATF2, and thus inhibiting the phosphorylation of ATF2 and formation of cellular ATF2-c-Jun complex induced by cisplatin. As the results, Hep-2/R cells failed to overexpress the Bcl-xl which is a key anti-apoptotic protein under the cisplatin treatment. Therefore, overexpression of miR-26b was found to be able to promote mitochondrial apoptosis induced by cisplatin.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20784